The QualityStocks Daily Tuesday, April 2nd, 2024

Today's Top 3 Investment Newsletters

Schaeffer's(VVPR) $5.9000 +306.90%

MarketClub Analysis(AINC) $4.7500 +113.96%

QualityStocks(BMXI) $0.0690 +96.72%

The QualityStocks Daily Stock List

Brookmount Explorations, Inc. (BMXI)

QualityStocks, Penny Picks, Damn Good Penny Picks, DSR News, Penny Stock Titans, Trading Wall St, OTCBB Journal, Shiznit Stocks, Penny Stock General, ProTrader, First Penny Picks, InvestorPlace, Monster Alerts, Nebula Stocks, Penny Stock 101, PennyStockLocks, PoliticsAndMyPortfolio, Winston Small Cap, Real Pennies, Small Cap Firm, SmallCapVoice, StockRockandRoll, StocksImpossible, StockTradingNetwork, TheMicrocapNews, Wall Street Resources and PHUB News reported earlier on Brookmount Explorations, Inc. (BMXI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A Nevada incorporated company, Brookmount Explorations, Inc. (BMXI) presently owns and operates two gold production facilities in Northern Indonesia. The Company is also in the process of reviewing acquisitions of additional operations in Indonesia and the Philippines. It is targeting the acquisition of high quality assets consisting of gold reserves that can undergo development via rapid and efficient deployment of technology and converted into cash flow to finance further expansion. Brookmount Explorations has its corporate headquarters in Los Angeles, California. It has also established an office in Melbourne, Australia and is seeking opportunities in what is one of the world’s leading gold producers. The Company lists on the OTC Markets.

At the end of August 2020, Brookmount Explorations, Inc. announced that it received consent from its Board of Directors that, subject to receipt of approval of a majority of the Company's shareholders, the name of the Company would be changed to Brookmount Gold Corporation from Brookmount Explorations, Inc. to reflect the Company’s status more accurately as an active operator and producer in the gold mining sector.

Brookmount Explorations’ existing operations consist of two key sites. One is Talawaan. This is a 50 hectare reserve and onsite processing facility situated in a high grade volcanic hosted sediment body in the district of Talawaan, next to the airport at Manado, regional capital. The facility has been in operation for 10 years. It has recently been upgraded and expanded. It consists of ball mills (ore crushers), 5 high capacity floatation tanks, tailing ponds, as well as off site smelting operations.

The Company also has a second site west of Manado with 2 contiguous areas totalling roughly 17 HA of high grade volcanic hosted ore. This site has also commenced production. Average ore grade of this property is in excess of 1.5g/tonne.

Brookmount Explorations, Inc. (BMXI), closed Tuesday's trading session at $0.069, up 96.7213%, on 2,895,856 volume. The average volume for the last 3 months is 171,031 and the stock's 52-week low/high is $0.022/$0.211.

Appili Therapeutics (APLIF)

BUYINS.NET, QualityStocks and MarketClub Analysis reported earlier on Appili Therapeutics (APLIF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Appili Therapeutics Inc. (OTCQX: APLIF) (TSE: APLI) is a biopharmaceutical firm that is engaged in the acquisition and development of new medications for unmet needs of infectious illnesses.

The firm has its headquarters in Halifax, Canada and was incorporated in 2015, on May 7th. It serves consumers in Canada.

The company’s aim is to build and advance an adverse portfolio of anti-infective programs. Its approach is focused on matching clearly defined medical needs with the opportunity for more effective solutions which range from improvements in current therapies to an entirely new class of anti-infectives. The company is party to a strategic alliance with AiPharma Global Holdings LLC, which entails the development of its Favipiravir formulation.

The enterprise’s portfolio comprises of its ATI-1701 candidate, which is a live-attenuated vaccine for Francisellatularensis; an oral suspension formulation of the metronidazole antibiotic dubbed ATI-1501, which is indicated for patients who have difficulty swallowing; and a drug discovery program dubbed ATI-1503, which develops a class of gram-negative targeting antibiotics. It also develops a clinical-stage antifungal candidate dubbed ATI-2307, which is in its clinical stage and is indicated for the treatment of invasive candidiasis and cryptococcal meningitis. In addition to this, the enterprise is engaged in the development of its Favipiravir candidate (Avigan/Reeqonus), for the treatment of the coronavirus and pandemic influenza.

The firm recently announced its financial results for the second quarter of its 2021 fiscal year, with its CEO noting that they achieved key development milestones, including the expansion of its drug development infrastructure, which will allow the firm to tackle infectious disease threats and advance its anti-infective pipeline.

Appili Therapeutics (APLIF), closed Tuesday's trading session at $0.037, up 74.5283%, on 3,790,720 volume. The average volume for the last 3 months is 9.047M and the stock's 52-week low/high is $0.0162/$0.0755.

KULR Technology Group (KULR)

AllPennyStocks, StockWireNews, QualityStocks, Fierce Analyst, Small Cap Firm, StockStreetWire, OTCtipReporter, Profitable Trader Authority, PennyStockScholar, PennyStockProphet, AwesomeStocks, Broad Street, Mega Stock Alerts, Penny Pick Finders, SmallCapVoice, PennyStockLocks, OTC Stock Review, MicroCapDaily, MarketClub Analysis, Buzz Stocks, StockOnion, StockRockandRoll, Penny Stock 101, Trades Of The Day, ProTrader, MarketBeat, InsiderTrades and HotOTC reported earlier on KULR Technology Group (KULR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

KULR Technology Group Inc. (NYSE American: KULR) is engaged in the development and commercialization of thermal management technologies for electronics, batteries and other components for various applications.

The firm has its headquarters in Campbell, California and was incorporated in December 2015 by Michael Mo. Prior to its name change in August 2018, the firm was known as KT High-Tech Marketing Inc. It serves consumers in the United States.

The company’s technologies are applied in various electronic applications where heat is usually an issue, like connected cars, drones, satellites, virtual reality platforms and mobile devices. The heat generated by the internal components of an electronic system can affect performance, decrease device lifespan as well as cause system failure. KULR owns carbon fiber-based thermal management solutions.

The enterprise provides CRUX cathodes, the LYRA ISC trigger cell, ARA thermal capacitor, internal short circuit devices, HYDRA TRS battery storage bags, phase change material heatsinks, fiber thermal interface materials and Li-ion battery thermal runaway shields. Its technologies are used in 5G communication devices, cloud computing, battery recycling transportation, energy storage and electric vehicles. The enterprise serves the battery transportation, energy storage and Li-ion battery markets, as well as the communication, space exploration, cloud computing, 5G mobile computing and electrical transportation markets.

The firm announced recently that it would be providing its Tech Safe Case to Heritage Battery Recycling, a company that recycles Li-ion batteries. The case has been designed to allow for safe transportation of batteries. The firm is well positioned to grow and acquire more investors, especially with the lithium-ion battery market expected to hit over $115 billion by 2030.

KULR Technology Group (KULR), closed Tuesday's trading session at $0.704, up 71.7073%, on 106,166,766 volume. The average volume for the last 3 months is 196 and the stock's 52-week low/high is $0.10/$1.10.

FIH Mobile Limited (FXCNF)

We reported earlier on FIH Mobile Limited (FXCNF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

FIH Mobile Limited (OTC: FXCNF) (HKG: 2038) is an investment holding firm engaged in the provision of integrated manufacturing services for the global handset industry.

The firm has its headquarters in New Taipei City, Taiwan and was incorporated in 2000, on February 8th. Prior to its name change in May 2013, the firm was known as Foxconn International Holdings Ltd. It operates as part of the communication equipment industry, under the technology sector. The firm serves consumers globally, with a focus on those in Europe, Asia, and the United States.

The company operates as a subsidiary of Hon Hai Technology Group (Foxconn).It operates through the following geographical segments: Asia, Europe, and America. A majority of its revenue is generated in Asia, with the rest coming from Europe and the America region.

The enterprise provides mobile phone complete end-to-end elements and manufacturing and engineering services, including product development and design, mandatory components, components, printed circuit board assembly (PCBA) and entire system assembly, and provides supply chain services, solutions, and repair and other after-sales services available in customer-neighboring locations. It also manufactures other wireless communication devices and electronic consumer products and accessories, as well as e-book readers, tablet and voice interactive products.

The firm,which recently became the first automotive supplier in Taiwan to pass the testing conducted by TÜV Rheinland and obtain Emergency Call (eCall) certification, remains committed to ongoing investment in innovative technology research and development to create outstanding value for customers. This will help drive long-term sustainable business growth while also encouraging more investments into the firm.

FIH Mobile Limited (FXCNF), closed Tuesday's trading session at $0.06265, even for the day. The average volume for the last 3 months is 2.598M and the stock's 52-week low/high is $0.057/$0.1123.

Cronos Group Inc. (CRON)

InvestorPlace, Schaeffer's, Kiplinger Today, MarketClub Analysis, StocksEarning, The Street, MarketBeat, Daily Trade Alert, QualityStocks, Trades Of The Day, Wealth Insider Alert, The Online Investor, Market Intelligence Center Alert, StockEarnings, StockMarketWatch, StreetInsider, BUYINS.NET, The Wealth Report, Zacks, Investopedia, Top Pros' Top Picks, Stock Up Featured, Daily Profit, Cabot Wealth, InvestmentHouse, Jim Cramer, Early Bird, InsiderTrades, The Rich Investor, Wall Street Window, InvestorsObserver Team, VectorVest, Money Morning, 24/7 Trader, TheTradingReport, Small Cap Firm, Stock Gumshoe and InvestorsUnderground reported earlier on Cronos Group Inc. (CRON), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The U.S. Department of Agriculture (“USDA”) recently gave the green light to genetically engineered hemp that doesn’t produce cannabidiol (“CBD”) or tetrahydrocannabinol (“THC”). This is the second genetically engineered variety of hemp to receive approval from the USDA. A low CBD-and THC strain by Growing Together Research was approved by the agency last year.

Hemp, under the 2018 Farm Bill, is defined as the cannabis sativa plant and any part with nothing more than 0.3% delta-9 THC concentration on dry weight basis. Anything above this limit is categorized as marijuana.

While there are different varieties of hemp that are low in THC, their THC concentration may surpass the limit due to a number of factors, including environmental ones. When this happens, farmers often have to destroy the crop and may sometimes even face criminal charges.

To help prevent this from occurring and farmers losing huge portions of their crop, genetic engineering has provided a number of solutions. For instance, investigators at the University of Wisconsin-Madison have developed a cannabis plant called Badger G that has no THC/THCA and CBD/CBDA. The researchers explained that their plant would offer growers in America compliance and agronomic benefits, including higher CBG levels.

For the plant to reach growers, however, some hurdles need to be overcome. For example, any plant developed using genetic engineering may receive exemption once a regulatory status review is completed. The review, carried out by the Animal and Plant Health Inspection Service (“APHIS”), determines if the crop is subject to regulations stipulated in the APHIS regulations at 7 CFR part 340.

Late last year, Michael Petersen, senior researcher at the Wisconsin Crop Innovation Center, made a request for a regulatory status review that sought an exemption for the center’s genetically modified cannabis plant. Earlier this week, the inspection service exempted the plant from the regulations. It should be noted that until the Animal and Plant Health Inspection Service completes this review, any genetically engineered crop isn’t eligible for exemption under 7 CFR 340.

In its statement, the body noted that the decision to exempt the genetically engineered plant from the regulations extended to any progeny of the plant derived from crosses with other nonaltered crops or other modified crops that also weren’t subject to the aforementioned regulations.

At this moment, it remains unclear when Badger G shall be made available commercially. It is expected to have a lot of demand, given the many benefits it offers farmers in particular. It would be interesting to get a glimpse into the possible plans that cannabis companies such as Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) would have regarding how to leverage such modified varieties of hemp.

Cronos Group Inc. (CRON), closed Tuesday's trading session at $2.65, up 0.378788%, on 3,552,497 volume. The average volume for the last 3 months is 441,313 and the stock's 52-week low/high is $1.64/$2.77.

Seelos Therapeutics Inc. (SEEL)

QualityStocks, MarketBeat, StockEarnings, StockMarketWatch, MarketClub Analysis, TradersPro, Schaeffer's, PsychedelicNewsWire, Prism MarketView, BUYINS.NET, Trades Of The Day and INO Market Report reported earlier on Seelos Therapeutics Inc. (SEEL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Recent research assessed how patient expectations influenced the outcomes of psychedelic treatments in comparison to conventional treatments. This comes as the global impact of depression is being felt in different parts of the world and the need for alternative treatments increases.

For a long time, selective serotonin re-uptake inhibitors (SSRIs) have been prescribed to manage depression. While these drugs do perform better than placebos, they aren’t effective for all individuals.

Psychedelic-assisted therapy has been heralded as a new approach to manage mental-health conditions such as depression, promising a range of benefits with only a few sessions. However, some questions on how expectations may contribute to positive outcomes observed in trials have been raised.

In recent research, researchers theorize that an individual’s expectations about a therapy’s outcome may influence the actual outcome. This is part of the placebo effect, where belief in a treatment’s effectiveness can cause actual improvements in symptoms regardless of whether an active therapeutic ingredient is active and present in the treatment. For their research, the scientists compared the use of psilocybin, a hallucinogenic compound found in some species of magic mushrooms, and escitalopram, a commonly prescribed antidepressant.

The researchers used blinding, a method used in trials to reduce biases. It works by ensuring that neither the scientists nor the participants know who is getting a placebo and who is receiving the actual treatment. The scientists conducted an analysis of data gathered during a double-blind trial that included 55 people who suffered from moderate to severe major depressive disorder. The participants were either given a placebo or psilocybin during the study period.

The researchers also evaluated traits such as absorption and suggestibility at baseline using the Modified Tellegen Absorption Scale and the Short Suggestibility Scale respectively.

To measure their expectations regarding the effectiveness of each treatment, the participants were asked to rate their anticipated improvement in their health. Generally, the participants were more optimistic about the outcome of psilocybin therapy in comparison to the other treatment.

Balázs Szigeti, the study’s first author and a data scientist at the Translational Psychedelic Research Program at UCSF, explained that the study found evidence that unblinding effects and expectancy were possible drivers of positive outcomes. In their report, however, the researchers noted that they observed no significant association between expectations and actual responses to psychedelic therapy. They also highlighted that people who were more receptive to the idea of psychedelic therapy could experience greater benefit from it.

The research’s findings were reported in the “Psychological Medicine” journal.

As it becomes clearer that the placebo effect isn’t having an undue influence on psychedelic research, the outcomes of the R&D programs of start-ups such as Seelos Therapeutics Inc. (NASDAQ: SEEL) will win over sceptics who were in doubt regarding the medicinal potential of psychedelic compounds.

Seelos Therapeutics Inc. (SEEL), closed Tuesday's trading session at $0.56, off by 4.2735%, on 200,313 volume. The average volume for the last 3 months is 26.071M and the stock's 52-week low/high is $0.3676/$49.80.

Tilray Brands Inc. (TLRY)

Schaeffer's, InvestorPlace, StocksEarning, StockEarnings, The Street, QualityStocks, MarketClub Analysis, MarketBeat, Trades Of The Day, Daily Trade Alert, StockMarketWatch, Kiplinger Today, StreetInsider, The Online Investor, Wealth Insider Alert, Market Intelligence Center Alert, BUYINS.NET, Zacks, Investopedia, CFN Media Group, CNBC Breaking News, Early Bird, The Street Report, Daily Profit, INO Market Report, StreetAuthority Daily, Inside Trading, The Rich Investor, Trading Concepts, Trading For Keeps, Tip.us, FreeRealTime, Top Pros' Top Picks, InvestmentHouse, InsiderTrades, Eagle Financial Publications, Investors Alley, Investment House, Outsider Club, wyatt research newsletter, Wealth Daily, VectorVest, TheTradingReport, The Night Owl, StrategicTechInvestor, MarketClub, Rick Saddler, InvestorsObserver Team, Money Morning, AllPennyStocks, Marketbeat.com, Louis Navellier, Jim Cramer, Jason Bond, InvestorsUnderground and Stock Up Featured reported earlier on Tilray Brands Inc. (TLRY), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Chuck Schumer, the Senate Majority Leader, is rallying public support for a bill focused on facilitating banking services for cannabis-related businesses through an online petition. In a recent communication concerning this endeavor, he reaffirmed his stance in favor of a comprehensive federal legalization of marijuana.

In the wake of continuing congressional discussions on budgetary appropriations, the SAFER Banking Act has come back into focus. Schumer, in an email communication, highlighted the challenges faced by state-licensed marijuana businesses in accessing banking facilities nationwide.

Schumer paints a picture of the predicament faced by these businesses, unable to access basic financial services such as credit lines or deposits due to the federal illegality of cannabis. Consequently, they are compelled to manage substantial cash reserves, a situation fraught with risks. Financial institutions remain wary of engaging with such enterprises given the conflicting legal landscape.

Further, he emphasizes the urgency of supporting the SAFER Banking Act to address these immediate concerns, employing a common tactic of online petitioning to galvanize support, leveraging it as a means for list-building and potential campaign fundraising.

Signatories are directed to a questionnaire probing their awareness of the marijuana banking issue, shedding light on the extent of the problem. The messaging underscores Senate Democrats’ commitment to assisting small businesses and rectifying the unjust legal status of cannabis. It solicits support to uphold the Democratic Senate Majority, hinting at donation avenues for those inclined to contribute.

The fate of the bill now rests with Schumer’s leadership. While the banking committee in the Senate endorsed the bipartisan measure months ago, its progression to the Senate floor hinges on scheduling. Nonetheless, there’s a palpable optimism among legislators regarding the measure’s prospects, buoyed by ongoing bicameral discussions.

Sherrod Brown, Chair of the Senate Banking Committee, has signaled the Act’s priority status despite acknowledging the complexities posed by prevailing House dynamics. Similarly, Tom Emmer, the House Majority Whip, although not a vocal advocate for marijuana reform, expressed a desire to advance the banking bill during a recent industry summit.

Disagreements over nonmarijuana provisions within the measure have stalled its advancement. Nevertheless, bicameral negotiations persist, with indications pointing towards an imminent resolution. Prominent sponsors from both parties have reaffirmed their commitment to shepherding the bill through Congress. Senator Maria Cantwell recently joined as the 36th cosponsor of the measure, further solidifying support within the chamber.

Should the bill proceed to the Senate this year, amendments are expected. Schumer has hinted at the possibility of incorporating provisions relating to gun rights for marijuana consumers and state-legal marijuana expungements.

The cannabis industry, including leading companies such as Tilray Brands Inc. (NASDAQ: TLRY) (TSX: TLRY) has long yearned for equal access to banking services in the way that other legitimate businesses access these services, but it looks like it may take a while for the needed legal reforms to be enacted at the federal level.

Tilray Brands Inc. (TLRY), closed Tuesday's trading session at $2.41, off by 0.823045%, on 43,468,212 volume. The average volume for the last 3 months is 132,809 and the stock's 52-week low/high is $1.50/$3.40.

FSD Pharma Inc. (HUGE)

QualityStocks, Schaeffer's, BUYINS.NET, StockMarketWatch, BioMedWire, PsychedelicNewsWire, MarketClub Analysis, StockEarnings, Penny Dreamers, InvestorPlace, CFN Media Group, bullseyeoptiontrading, Broad Street and AwesomeStocks reported earlier on FSD Pharma Inc. (HUGE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has filed its audited annual financial results. According to the announcement, the results are for Q4 and the full fiscal year for the period ending Dec. 31, 2023. The company also announced that it had filed accompanying management's discussion and analysis.

To view the full press release, visit https://ibn.fm/L6trI

About FSD Pharma Inc.

FSD is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), FSD is focused on the research and development of its lead compound, Lucid-MS (formerly Lucid-21-302) (“Lucid-MS”). Lucid-MS is a patented new chemical entity shown in preclinical models to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. FSD Pharma has also licensed unbuzzd(TM), a proprietary formulation of natural ingredients, vitamins and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption for use in the consumer recreational sector, to Celly Nutrition Corp; FSD Pharma is entitled to a royalty on the revenue generated by Celly Nu from sales of products created using the technology rights granted under the licensing agreement. FSD Pharma continues its R&D activities to develop novel formulations for alcohol-misuse disorders and continues the development of such treatments for use in the healthcare sector. FSD Pharma also maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represent loans secured by residential or commercial property. For more information about the company, please visit www.FSDPharma.com.

FSD Pharma Inc. (HUGE), closed Tuesday's trading session at $0.67, off by 3.1162%, on 35,375 volume. The average volume for the last 3 months is 98,265 and the stock's 52-week low/high is $0.65/$2.10.

HealthLynked Corp. (HLYK)

QualityStocks, PCG Advisory, Trades Of The Day, PoliticsAndMyPortfolio and BioMedWire reported earlier on HealthLynked Corp. (HLYK), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

HealthLynked (OTCQB: HLYK), a leader in healthcare networking and technological innovation, is reporting financial results for Q4 and full year ended Dec. 31, 2023. A highlight of the report includes that, based on “strategic advancements and its focus on core healthcare technologies and networking capabilities, HealthLynked achieved a significant 70% reduction in net loss for the fourth quarter, highlighting a period of fiscal management and strategic positioning for future growth.” The report noted that the company’s strategic focus and technological innovations are paving the way for an optimistic outlook with optimization of operational expenses leading to a 52% cut in operational losses. In addition, the company’s strategic sale of ACO Health Partners brought in $3.76 million and contributed to HealthLynked’s financial restructuring while also bolstering the company’s liquidity and financial resilience. “The recent launch of our pay app version 3.2.1 and the forthcoming integration of ARI mark significant milestones in our mission to transform healthcare delivery and drive additional revenues,” said HealthLynked CEO Dr. Michael Dent in the press release. “Despite temporary staffing transitions, our focus on our core healthcare network and technological innovations positions us for substantial growth and profitability. We continue to grow our user base while integrating technology that improves patient care and the efficient exchange of medical information between doctors and patients.”

To view the full press release, visit https://ibn.fm/p3UXp

About HealthLynked

HealthLynked is dedicated to improving global community health. The company’s mission unfolds in two pivotal goals: First, to transform healthcare into a system marked by enhanced efficiency and improved care for all, leveraging cutting-edge technology and connectivity. Second, to forge a patient-centric network that not only places patients at the heart of their healthcare journey but also mobilizes their participation to accelerate medical discoveries and the development of cures for diseases that impact humanity. This pioneering model empowers individuals with unparalleled access to and control over their medical information, fostering a collaborative environment where every patient contribution can spearhead breakthroughs in health and wellness. Through these concerted efforts, the company aims to secure a healthier future for generations to come. At the heart of the company’s endeavors is the HealthLynked Network, a sophisticated, cloud-based platform designed to facilitate the seamless exchange of medical information among patients and healthcare providers. By centralizing and securing medical data — including medications, allergies, past surgeries and personal health records — HealthLynked members are empowered to take an active role in managing their healthcare with unparalleled ease and efficiency. For more information about the company, please visit www.HealthLynked.com.

HealthLynked Corp. (HLYK), closed Tuesday's trading session at $0.05205, off by 17.381%, on 24,182 volume. The average volume for the last 3 months is 1.035M and the stock's 52-week low/high is $0.033/$0.1039.

Danimer Scientific (DNMR)

Schaeffer's, Kiplinger Today, MarketBeat, QualityStocks and MarketClub Analysis reported earlier on Danimer Scientific (DNMR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Danimer Scientific (NYSE: DNMR) is a leading next- generation bioplastics company focused on the development and production of biodegradable materials. The company recently announced the closing of its registered direct offering for the purchase and sale of 15,000,000 shares of common stock (or common stock equivalent in lieu thereof) at a purchase price of $1.00 per share (or per common stock equivalent in lieu thereof) and accompanying warrants to purchase up to an aggregate of 15,000,000 shares of common stock. Danimer secured approximately $15 million in gross proceeds, of which it intends to use the net for working capital and general corporate purposes. Roth Capital Partners acted as the exclusive placement agent for the offering.

To view the full press release, visit https://ibn.fm/kexh8

About Danimer Scientific Inc.

Danimer is a pioneer in creating more sustainable, more natural ways to make plastic products. For more than a decade, its renewable and sustainable biopolymers have helped create plastic products that are biodegradable and compostable and return to nature instead of polluting our lands and waters. Danimer’s technology can be found in a vast array of plastic end products that people use every day. Applications for its biopolymers include additives, aqueous coatings, fibers, filaments, films and injection-molded articles, among others. Danimer holds more than 480 granted patents and pending patent applications in more than 20 countries for a range of manufacturing processes and biopolymer formulations. For more information about the company, visit https://danimerscientific.com.

Danimer Scientific (DNMR), closed Tuesday's trading session at $1.06, up 0.952381%, on 615,094 volume. The average volume for the last 3 months is 6.99M and the stock's 52-week low/high is $0.60/$4.59.

Astera Labs (ALAB)

MarketBeat and Early Bird reported earlier on Astera Labs (ALAB), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Astera Labs (NASDAQ: ALAB) has announced the pricing of its initial public offering of 19,800,000 shares of its common stock at a price to the public of $36.00 per share. According to the announcement, the offering consists of 16,788,903 shares of common stock offered by Astera Labs and 3,011,097 shares of common stock to be sold by certain of Astera Labs’ existing stockholders. In addition, the underwriters will have a 30-day option to purchase up to an additional 2,970,000 shares of common stock from Astera Labs at the initial public offering price, less underwriting discounts and commissions. The gross proceeds to the company are expected to be approximately $604.4 million, with the shares expected to begin trading on the Nasdaq Global Select Market under the ticker symbol ALAB on March 20, 2024. Subject to customary conditions, the offering is expected to close on March 22, 2024.

To view the full press release, visit https://ibn.fm/yZkeC

About Astera Labs Inc.

Astera Labs is a global leader in purpose-built connectivity solutions that unlock the full potential of AI and cloud infrastructure. Its Intelligent Connectivity Platform integrates PCIe(R), CXL(R) and Ethernet semiconductor-based solutions based on a software-defined architecture that is both scalable and customizable. Inspired by trusted relationships with hyperscalers and the data center ecosystem, Astera Labs is an innovation leader delivering products that are flexible and interoperable. Discover how Astera Labs is transforming modern data-driven applications at www.AsteraLabs.com.

Astera Labs (ALAB), closed Tuesday's trading session at $72.21, up 1.5326%, on 2,024,116 volume. The average volume for the last 3 months is 141,419 and the stock's 52-week low/high is $50.61/$95.21.

AppTech Payments Corp. (APCX)

Hot Shot Stocks, OTCPicks, QualityStocks, HotStockCafe, Penny Stock Chaser, Stock Traders Chat, FeedBlitz, Fierce Analyst, PennyTrader Publisher, Wise Alerts, Small Cap Firm, StockEgg, StockStreetWire, StockWireNews, Penny Invest, CoolPennyStocks, HotOTC, OTCReporter, Penny Stock Rumble, BullRally, The Cervelle Group, Stock Source, Real Pennies, PennyTrader, MicrocapVoice, Innovative Marketing, The Stock Dork, SeriousTraders, TheStockWizards.net, Greenbackers, TopPennyStockMovers, Virmmac Team, Stock Rich and The Penny Stock Alert reported earlier on AppTech Payments Corp. (APCX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

AppTech Payments (NASDAQ: APCX), a pioneering fintech company powering frictionless commerce, has closed on a previously announced underwritten public offering. The offering was comprised of 2,000,000 shares of common stock at $1 per share. The offering is valued at an estimated $2 million in gross proceeds, before deducting underwriting discounts and other offering expenses. The announcement noted that APCX also granted the underwriters a 45-day option to purchase up to an additional 300,000 shares of common stock to cover any overallotments. EF Hutton LLC acted as sole bookrunner for the offering.

To view the full press release, visit https://ibn.fm/G189g

About AppTech Payments Corp.

AppTech Payments Corp. provides digital financial services for financial institutions, corporations, small- and midsized enterprises, and consumers through its scalable cloud-based platform architecture and infrastructure, coupled with its Specialty Payments development and delivery model. AppTech maintains exclusive licensing and partnership agreements in addition to a full suite of patented technology capabilities. For more information, visit the company website at www.AppTechCorp.com.

AppTech Payments Corp. (APCX), closed Tuesday's trading session at $0.9398, off by 1.1257%, on 211,234 volume. The average volume for the last 3 months is 3,209 and the stock's 52-week low/high is $0.9044/$4.81.

The QualityStocks Company Corner

Astrotech Corp. (NASDAQ: ASTC)

The QualityStocks Daily Newsletter would like to spotlight Astrotech Corp. (NASDAQ: ASTC).

Astrotech (NASDAQ: ASTC), an innovative science and technology company, and its wholly owned subsidiary, 1st Detect Corporation, will be showcasing the TRACER 1000 Narcotics Trace Detector ("NTD") and Explosives Trace Detector ("ETD") at the International Security Conference and Exposition. Known as ISC West, the conference and expo is slated to run April 9–12, 2024, in Las Vegas; the event is the one of the leading comprehensive security trade events in the nation and will be attended by key security and public-safety professionals. A high-performance laboratory instrument powered by Astrotech Mass Spectrometer Technology(TM), the TRACER 1000 can detect trace levels of narcotics or explosive compounds in seconds. The device is the first mass spectrometry-based ETD to receive European Civil Aviation Conference ("ECAC") certification for both checkpoint and cargo security and can be used in an array of sectors, including airports, border security, checkpoint, cargo, infrastructure security, correctional facilities, military and law enforcement. "We are extremely excited to share our user-friendly mass spectrometer, the TRACER 1000, which is powered by our AMS Technology, with leading industry experts and security-industry professionals at the ISC West conference," said Astrotech chair, CEO and CTO Thomas B. Pickens III in the press release. "This allows us a platform to reach those in the industry across various markets, such as security, checkpoint, military and law enforcement, that strive for quality instrumentation, that require a minimum amount of maintenance and [that] want accurate but rapid detection."

To view the full press release, visit https://ibn.fm/isAYK

Astrotech Corp. (NASDAQ: ASTC) is an instrumentation company that designs, manufactures and commercializes solutions. Its solutions include mass spectrometry, process controls, chemical detectors and medical disease detection.

The company was established in 1984 and, prior to 2009, was known as SPACEHAB Inc., a NASA contractor offering technology originally developed for NASA to monitor air quality on the International Space Station. When the Space Shuttle program ended, the company focused on its satellite processing and mass spectrometer instrumentation units and adopted the Astrotech name.

In 2014, Astrotech sold its satellite subsidiary to focus on its Astrotech Technology Inc. (ATi) mass spectrometry solutions, which offer a number of advantages over competing platforms. Notably, Astrotech’s ATi technology is ruggedized, rapid, simple to use and customizable, with hands-free calibration and tuning.

Between 2016 and 2019, the company secured U.S. patents for its technology and achieved European Union (ECAC) certification for the TRACER 1000™, the world’s first mass-spec Explosives Trace Detector (ETD) used in airports worldwide. Astrotech continues to innovate and add to its suite of products, including AgLAB-1000, a process control system, and the BreathTest 1000, a disease detection solution.

Astrotech is headquartered in Austin, Texas.

Subsidiaries

Astrotech Technologies Inc.

Astrotech Technologies Inc. (ATi) owns and licenses the platform mass spectrometry technology originally developed by 1st Detect. This technology is designed to be less expensive, smaller and easier to use than traditional mass spectrometers.

Unlike other technologies, ATi works under high vacuum, which eliminates competing molecules, yielding higher resolution and fewer false alarms. The company’s intellectual property includes 18 granted patents, along with extensive trade secrets.

ATi exclusively licenses the Astrotech Mass Spectrometer Technology to the three wholly owned subsidiaries of Astrotech.

1st Detect Corp.

1st Detect Corp. developed the TRACER 1000, the world’s first mass spectrometry-based explosives and narcotics trace detector. 1st Detect ETDs were developed for use at airports, cargo facilities and other secured locations and borders worldwide.

1st Detect’s commercial sales of the TRACER 1000 ETD, consumables and recurring maintenance services brought in $750,000 in total revenue during the fiscal year ended June 30, 2023. The Astrotech subsidiary recently secured two orders for a total of 24 Tracer 1000 units from two Romanian security and telecommunications companies, to be delivered during calendar 2023.

AgLAB Inc.

AgLAB Inc. is developing a series of mass spectrometers for use in the hemp and cannabis market, with an initial focus on optimizing yields in the distillation processes.

AgLAB, which uses the company’s proprietary AgLAB 1000-D2™ mass spectrometer, has been proven to improve distillation oil yields and bottom-line profits for hemp and cannabis producers. During field trials, AgLAB was able to improve ending-weight yields by an average of 24%.

BreathTech Corp.

BreathTech is developing the BreathTest-1000™, a breath analysis tool to screen for volatile organic compound (“VOC”) metabolites found in a person’s breath that could indicate they may have a compromised condition including but not limited to a bacterial or viral infection. The company believes that new tools to aid in the battle against COVID-19 and other diseases remain of the utmost importance to help more quickly identify that an infection may be present.

Market Opportunity

A report by Mordor Intelligence, a research and advisory firm, put the global mass spectrometry market at $6.37 billion in 2023. The market is forecast to grow to $8.63 billion by 2028, achieving a CAGR of 6.25% during the forecast period.

One of the major driving factors for the growth of the mass spectrometry market is technological advancements in mass spectrometer devices, the report states. Key market players are continuously working toward advancing their existing products and launching innovative and advanced mass spectrometer devices.

Another major factor that is expected to boost market growth is increasing research and development expenditure by both government and private entities, according to the report. Mass spectrometry devices are also being used in the detection and analysis of COVID-19 and other disease samples, which may have a positive impact on the market.

Management Team

The Astrotech leadership team includes management executives, as well as industry and technology experts. The company continues to actively expand its talent pool to meet evolving demands.

Thomas B. Pickens III is Chairman, CEO and Chief Technology Officer of Astrotech Corp. He also serves as CEO of Astrotech subsidiaries ATi, 1st Detect, AgLAB Inc. and BreathTech Corp. Previously, he was the founder and president of Beta Computer Systems Inc. and T.B. Pickens & Co. He was founder and general partner of Grace Pickens Acquisition Partners L.P and managing partner of Sumpter Partners. He also served as CEO of Catalyst Energy Corporation and United Thermal Corporation and as president of Golden Bear Corp., United Hydro Inc. and Slate Creek Corp. He received a B.A. in Economics, Computer Science and Engineering from Southern Methodist University.

Jaime Hinojosa, CPA, is CFO at Astrotech Corp. He joined the company in 2015 and has served as its Corporate Controller since 2019. His previous roles with the company include Director of Finance, from 2017 to 2019, and Assistant Controller, from 2015 to 2017. Prior to joining Astrotech, Mr. Hinojosa worked as an Accounting Manager for O’Reilly Auto Parts and gained public accounting experience as an Audit Manager at Burton McCumber & Cortez LLP.

Astrotech Corp. (NASDAQ: ASTC), closed Tuesday's trading session at $8.65, up 0.289855%, on 816 volume. The average volume for the last 3 months is 483,422 and the stock's 52-week low/high is $7.00/$15.11.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has received three new patent awards. According to the announcement, the company was awarded two new patents in its epilepsy patent family; both awards were granted in the United States. The U.S. patents, which cover both swallowed capsules and dissolvable oral tablets, complement research indicating DehydraTECH-CBD has potential to decrease epileptic seizures in rodents and to be absorbed into the bloodstream more effectively than the current treatments. In addition, Lexaria was awarded a patent in Japan in is antiviral agent patent family. The new patents bring the total of Lexaria patents to 41 worldwide.

To view the full press release, visit https://ibn.fm/N1TzQ

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has also collaborated with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has been granted patent protection for specific delivery of nicotine, vitamins, NSAIDs, antiviral drugs, cannabinoids and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Tuesday's trading session at $3.47, up 1.462%, on 134,543 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $15.11/$.

Recent News

Zoned Properties Inc. (OTCQB: ZDPY)

The QualityStocks Daily Newsletter would like to spotlightFathom Zoned Properties Inc. (OTCQB: ZDPY).

Zoned Properties is a leader in cannabis real estate development, with a sophisticated PropTech stack to spearhead a direct-to-consumer real estate model

Zoned Properties reported a net profit of $114,523 during the quarter ended September 30, 2023

ZPDY has listed a property for sale at a price of $16 million, non-dilutive capital that will be used to continue to fund growth

The cannabis industry is experiencing explosive growth, but its infrastructure often lags behind. Green Zones – compliant locations and properly permitted real estate – are part and parcel to unlocking the industry's full potential. This focus not only fuels the industry's expansion by providing investment-ready properties, but also underscores a commitment to fostering responsible growth through community-focused infrastructure. Technology-driven companies like Zoned Properties (OTCQB: ZDPY) are playing a vital role as stewards of this green revolution. Zoned Properties (OTCQB: ZDPY), a technology-driven property investment company for emerging and highly regulated industries, is seeking to capitalize on the U.S. cannabis industry's burgeoning future by targeting commercial properties with the potential to be acquired and rezoned or permitted for specific purposes. "Zoned Properties maintains a portfolio of six investment properties located across Arizona, Michigan and Illinois, with each of its leased properties occupied by commercial cannabis-linked businesses. The company currently enjoys a 100% occupancy rate with a weighted average lease term of over 10 years. In addition to maintaining four properties leased and repurposed as regulated cannabis retail dispensaries, the company leases two properties that are operated as regulated cannabis cultivation and processing facilities," a recent article reads. "Nonetheless, the company has recently sought to refocus its investment portfolio towards direct-to-consumer properties located in states boasting both a regulated and legal domestic cannabis industry and robust underlying cannabis consumer demand. In doing so, Zoned Properties has announced that it now considers its cultivation sites as legacy properties, reserving the optionality to potentially sell or leverage these holdings to unlock equity to be deployed towards its core business."

To view the full article, visit https://cnw.fm/TM2gl

Zoned Properties Inc. (OTCQB: ZDPY) is a technology-driven property investment company focused on acquiring value-add real estate within the regulated cannabis industry in the United States. The company aspires to innovate within the real estate development sector, focusing on direct-to-consumer real estate that is leased to best-in-class cannabis retailers.

The company is redefining the approach to commercial real estate investment through its standardized investment process backed by its proprietary property technology. Zoned Properties has developed a national ecosystem of real estate services to support its real estate development process, including a commercial real estate brokerage and a real estate advisory practice.

With a decade of national experience and a team of experts devoted to the emerging cannabis industry, Zoned Properties is addressing the specific needs of a modern market in highly regulated industries. The company targets commercial properties that face unique zoning or development challenges, identifies solutions that can potentially have a major impact on their commercial value and then works to acquire the properties while securing long-term, absolute-net leases.

Zoned Properties targets commercial properties that can be acquired and rezoned for specific purposes, including the regulated and legalized cannabis industry. It does not grow, harvest, sell or distribute cannabis or any substances regulated under United States law.

The company is headquartered in Scottsdale, Arizona.

Portfolio

The company’s investment properties are located in Arizona, Michigan and Illinois, with 100% occupancy and a weighted average lease term over 10 years. Each of the company’s leased properties is occupied by a commercial cannabis tenant. The company is expecting rental revenue from its property investment portfolio of greater than $2.5 million in calendar-year 2024.

Zoned Properties maintains a portfolio of properties that it owns, develops and leases. As of February 2024, the company leases land and/or building space at the six properties in its portfolio to licensed and regulated cannabis tenants in areas with established cannabis regulations and zoning procedures. Four of the leased properties are zoned and permitted as regulated cannabis retail dispensaries, and two of the leased properties are zoned and permitted as regulated cannabis cultivation and processing facilities.

The company considers the two cultivation sites in its portfolio as legacy properties and may consider selling or leveraging those properties to unlock equity and create capital availability in the future. The Zoned Properties investment thesis has evolved over the years as the cannabis industry has emerged, and the company is currently focused on investing capital into direct-to-consumer properties, located in state-markets with robust cannabis consumer demand in the industry.

Zoned Properties is in pursuit of property acquisitions that can be characterized as consumer-facing, retail dispensary properties that are positioned to be leased to retail dispensary cannabis tenants under net leasing structures. As of September 2023, the company has agreements in place to acquire new investment properties with new cannabis tenants located in Arizona, Missouri and Illinois. The company plans to initiate and target its investment process in Ohio and Maryland.

With a strategic shift in focus to direct-to-consumer real estate that is leased to best-in-class cannabis retailers in the industry, the company will continue to utilize its competitive edge when identifying excellent investment properties. Zoned Properties has a full pipeline of acquisition prospects and continues to utilize an extremely disciplined capital allocation approach.

Market Opportunity

According to MJBizDaily, a publication that has covered the North American cannabis business since 2011, combined U.S. medical and recreational cannabis sales were estimated at approximately $33.6 billion at the end of 2023, largely driven by the opening of new adult-use markets.

The publication projects that combined U.S. retail cannabis sales will reach upwards of $53.5 billion by 2027, according to an analysis published in its volume of cannabis market research, the MJBiz Factbook.

As of February 2024, 38 U.S. states had legalized medical, recreational or other limited use of cannabis. The Pew Research Center reports that, in January 2023, there were more than 11,000 licensed cannabis dispensaries in the U.S. In addition, global research firm IBISWorld reports that more than 40,000 U.S. localities have adopted regulations governing cannabis usage, production, processing and/or dispensing.

Management Team

Bryan McLaren is the Chairman and CEO of Zoned Properties. Previously, he worked as a Sustainability Consultant for Waste Management Inc., where he led the strategic development and operational implementation of zero-waste programs for clients. He was also appointed as a city Sustainability Commissioner. He holds a bachelor’s degree in business administration from the University of San Diego, a master’s degree in sustainable development from Northern Arizona University, an executive master’s degree in business leadership from Arizona State and an MBA with a specialty in sustainable development.

Berekk Blackwell is the President and COO of Zoned Properties. He previously spent time in developing domestic and international markets for Kahala Brands, a conglomerate of over 15 QSR franchises, including Cold Stone Creamery and Blimpie Subs. He later worked on developing QSR concepts for Revamp Corp. in Tokyo. After returning to the U.S., he served as president of Daily Jam, a limited-service breakfast and brunch chain. He holds a bachelor’s degree in business administration in finance from Fort Lewis College.

Patrick Moroney is the Director of Real Estate Acquisitions for Zoned Properties. Previously, he was one of the most successful Associate Brokers at Kidder-Mathews, focusing primarily on the regulated cannabis industry. He also worked as a commercial real estate broker rep at Cushman & Wakefield and Colliers International. He graduated from Arizona State University, after which he spent four years as a local sports broadcaster in Georgia and Iowa.

Kyle Gere is the Director of Advisory Services at Zoned Properties. He has years of licensing experience across multiple U.S. states in the medical and recreational cannabis markets. Since 2015, he has been involved in cannabis real estate transactions in Arizona and Michigan, managing a portfolio of medical marijuana properties. He attended Northern Arizona University, graduating with a bachelor’s degree in business administration in both management and marketing.

Zoned Properties Inc. (OTCQB: ZDPY), closed Tuesday's trading session at $0.51, up 2.5229%, on 8,950 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.35/$0.80.

Recent News

Horizon Fintex | Upstream

The QualityStocks Daily Newsletter would like to spotlight Horizon Fintex | Upstream

Upstream, a MERJ Exchange market and trading app, has published a blog that discusses the exciting possibilities in the world of digital collectibles. Among these is the ability for airdrops to unlock potential for brands, companies and their audiences.

The piece reads, "Airdrops serve as not just a gateway to the exciting world of Web3, but a way to interact with your fans… Build Your Online Presence: Reward your biggest fans with digital rewards or collectibles tied to specific events, locations, milestones, content, etc. These collectibles introduce digital ownership and can decorate your online persona and your fans' online personas. Unlock Revenue Potential: Start with free collectibles, then lead into collectibles available for purchase to further your initiatives and increase the tangible benefits associated with digital collectibles. Access Real-Time Insights: Drive meaningful user journeys and track audience interactions with timestamped loyalty rewards, enabling you to tailor your offerings effectively."

To view the full blog, visit https://ibn.fm/Qz92Q

Horizon Fintex is a software business specializing in compliant securities solutions. The company aims to facilitate the future of capital markets by leveraging the regulatory experience of Wall Street bankers and the proven track record of technology veterans to bring focus to compliance, efficiency, security and transparency.

Horizon’s flagship product is the revolutionary trading app ‘Upstream’, a MERJ Exchange Market, and the first regulated market powered by a blockchain to offer both digital securities and NFT trading. Upstream traders experience T+0 settlement, best bids and offers displayed on a transparent public orderbook that prevents predatory market practices – all from a user-friendly trading app.

Products

Horizon Fintex offers a full suite of end-to-end blockchain-enhanced software solutions to create a seamless experience for both issuers and investors. Its product suite includes:

  • Securitization & Issuance – ETSware is an end-to-end Electronic Trading System streamlining capital raising from primary issuance through compliant secondary trading.
  • KYC Compliance Onboarding – KYCware is a white label Know Your Customer (KYC) and Anti-Money Laundering (AML) compliance software solution offering best-in-class cryptographic security to compliantly onboard and verify user identity through a smartphone application.
  • AML Screening Software – AMLCop offers advanced Anti-Money Laundering (AML) software to streamline the verification of user details against a proprietary database of global sanctions, politically exposed persons (PEPs) and watchlists.
  • Cap. Table Management Tools – CustodyWare equips registered U.S. transfer agents with next-generation cap. table management software to manage securities on behalf of their clients pursuant to an SEC-registered or exempt securities offering.
  • Exchange & Trading App Technology – Open Order Book offers Ethereum blockchain securities exchange software to power the next generation of trading venues for digital assets.

Upstream – The Horizon-Powered Trading App

Upstream is a joint venture with MERJ Exchange (merj.exchange), an affiliate of the World Federation of Exchanges.

Upstream aims to be the premiere global trading hub offering issuers around the world exposure to a digital-first investor base that can trade using USDC digital currency along with credit, debit, PayPal, and USD (fiat) to increase liquidity and enhance price discovery; while also offering investors access to dual-listed companies, IPOs, crowdfunded companies, U.S. & Int’l. equities, digital coupons and NFTs directly from a user-friendly trading app.

Upstream aims to unlock liquidity for investors of all levels while offering industry-leading levels of transparency, accessibility and investor protections enforced using Ethereum blockchain technology.

Management Team

Brian Collins is the CEO of Horizon Fintex. He founded the company in 2010. From 1999-2010, Mr. Collins was CEO of Abbey Technology in Switzerland, specializing in the design of trading software for Swiss banks. Prior to this, he worked for Credit Suisse in Zürich, designing and building proprietary equity trading solutions. Mr. Collins graduated in 1990 with a BS in Computer Systems from the University of Limerick, Ireland.

Mark Elenowitz is the company’s President. He is a Wall Street veteran with over 29 years of experience. Mr. Elenowitz was the co-founder of a U.S. broker dealer and is Managing Director of two U.S. broker dealers, responsible for advising clients on compliance, capital structure and capital market navigation. He was responsible for leading the first successful Reg A+ IPO of a company to list on the NYSE and others which listed directly onto Nasdaq. He is a noted speaker at Small Cap and Reg A events, including the SEC Small Business Forum, and has been profiled in BusinessWeek and CNBC, as well as several other publications. Mr. Elenowitz is a graduate of the University of Maryland School of Business and Management with a BS in Finance and holds Series 24, 62, 63, 79, 82 and 99 licenses.

Dr. Andrew Le Gear is the CTO of Horizon Fintex. Prior to joining the company in 2013, he worked as a software engineer with Dell Inc. (2012-2013) and Lehman Brothers and Nomura Plc. (2007-2012). Dr. Le Gear was a co-founder of Juneberi Ltd., a research-driven software tech start-up (2004-2007). He graduated in 2006 with a Ph.D. in Computer Science from the University of Limerick, Ireland.

Peter Hall is the company’s CIO. Prior to joining Horizon Fintex in 2011, he worked at Microsoft (2008-2011), Atos Origin (2004-2008) and AIT Group Plc. (1998-2002). Mr. Hall has held CISSP certification since 2010. He graduated from the University of Sheffield, UK in 1995 and earned an MS from the University College London in 2006.

Mike Boswell is the CFO of Horizon Fintex. A Wall Street veteran, he co-founded a U.S. broker dealer and served as Chief Compliance Officer. Mr. Boswell was also Managing Director of TriPoint Capital Advisors, a merchant banking and financial consulting company, and CFO of Mission Solutions Group, a privately held defense sector firm. He earned an MBA from John Hopkins University and a BS in Mechanical Engineering from the University of Maryland. Mr. Boswell holds Series 24, 62, 63, 79, 82 and 99 licenses.

Recent News

chart

Astiva Health

The QualityStocks Daily Newsletter would like to spotlight Astiva Health

Astiva Health, a leading provider that specializes in delivering personalized and comprehensive healthcare solutions to diverse communities, is championing a model of care that emphasizes proactive health management and a healthy lifestyle over traditional reactive methods. "At the core of Astiva Health's innovative approach is the principle of patient-centric care. This method prioritizes the active involvement of patients in their healthcare decisions, ensuring their preferences, needs and values guide their care plans… A critical element in Astiva Health's strategy is the development of a supportive health community. This community – encompassing healthcare professionals, family, caregivers, and peer groups – provides a comprehensive network of resources and support. Such a community-focused approach facilitates knowledge exchange and is particularly advantageous in managing chronic conditions, which are prevalent among older adults," a recent article explains. "Astiva Health's proactive healthcare model extends beyond basic services, offering a wide range of resources addressing the physical, mental and social facets of health. Initiatives such as fitness programs, grocery benefits, nutritional guidance, easily accessible transportation services and mental health support aim to promote a healthy lifestyle. These resources play a pivotal role in maintaining independence, enhancing the quality of life and potentially preventing severe health issues. Technology plays a crucial role in Astiva Health's mission to deliver patient-centric health and build a supportive community… Astiva Health is not merely addressing diseases; it's advocating for a comprehensive, proactive approach to health that places individuals in command of their well-being… By prioritizing patient involvement and embracing technology, Astiva Health is setting a new standard for effective, fulfilling and sustainable healthcare for the aging population."

To view the full article, visit https://ibn.fm/yRncb

Astiva Health is a dynamic and innovative Medicare Advantage Prescription Drug (MAPD) health plan committed to reshaping the landscape of personalized and comprehensive healthcare. The company offers full medical, drugs, and supplemental benefits for Medicare enrollees, currently serving counties in California, including Orange, San Diego, Los Angeles, Riverside, and San Bernardino. This broad coverage reflects Astiva Health’s dedication to reaching a diverse demographic and addressing the healthcare needs of individuals across Southern California.

Astiva Health primarily serves a heretofore underserved Asian American and Pacific Islander population, which positions it in a critical and expanding market segment and offers substantial growth potential. The company recognizes the diverse needs within its served communities and strives to bridge healthcare gaps through proactive and culturally responsive solutions.

Astiva Health cares about its members and works to establish lifelong relationships with them by providing a tailored approach to healthcare, offering multilingual solutions for customer service, marketing materials and educational resources. Health is an essential key to living a good life, and Astiva Health makes it a priority to help members love the life they live.

The company’s mission is to deliver an unparalleled level of quality care to its members. Astiva Health’s Medicare Advantage plans provide lower costs and additional benefits beyond original Medicare coverage.

Founded in southern California, Astiva Health has strategically positioned itself in a region with a dynamic and diverse population. The organization’s extensive network and culturally responsive approach to healthcare make it well-suited to cater to the needs of the local community, creating a competitive advantage in the market.

The company is based in Orange, California.

Healthcare Model

Astiva Health is not just another health plan. The company considers the uniqueness of its members and, therefore, the means for delivering quality care to each one. To best serve its members, Astiva Health has developed one of the most diverse networks in southern California, offering a selection of medical, drugs, and supplemental benefits including dental, acupuncture, vision and hearing plans tailored to the specialized needs of individual members.

The company’s health plans provide increasing levels of benefits to members in the counties it serves. Astiva Health’s Customer Care Support and representatives are available to assist members with any issues.

The organization’s proactive approach to overcoming language barriers for the Vietnamese communities demonstrates a commitment to inclusivity and enhances accessibility – a key factor for future growth. The successful implementation of strategies for the Vietnamese community sets a precedent for Astiva Health’s ability to adapt and apply similar approaches to serve other ethnic groups in future expansions, broadening the potential impact of its services.

The company provides members access to experienced and dedicated providers and local pharmacies that work together with each member to pave a pathway toward better health. The company’s online directory provides members with a comprehensive list of providers to fit their specialized needs.

Astiva Health collaborates with a variety of partners who offer supplemental benefits to members beyond Medicare. Those benefits include transportation, vision, dental, hearing, fitness, tele-health, acupuncture and chiropractic. Astiva’s forward-thinking strategy not only fulfills a critical societal need but also ensures sustainable growth and transformative impact across diverse communities.

Market Opportunity

Medicare Advantage plans, since their establishment in 2008 as a lower-cost alternative for Medicare enrollees looking to save on monthly premiums, have been one of the fastest growing segments of the health insurance market.

According to a report by healthcare consultant Charts, nearly 31 million beneficiaries are enrolled in a Medicare Advantage plan in 2023, accounting for more than 48% of the total Medicare market. That represents 9.6% enrollment growth over 2022 totals, and the pace of growth is likely to continue, according to the Charts report.
Startup Medicare Advantage plans, a sector that includes Astiva Health, grew even faster for 2023, at a rate of 22% over 2022 totals.

Management Team

Dr. Tri T. Nguyen is co-founder and CEO of Astiva Health. He is a graduate of Stanford Medical School and is a board-certified expert in internal medicine, cardiovascular disease and interventional cardiology. As founder, CEO and owner/operator of Avanta IPA, he is a committed leader in healthcare. His visionary leadership, hands-on experience and deep industry knowledge uniquely position him to guide Astiva to success.

Chi Luong is CFO at Astiva Health. She founded and operates HADD Group LLC, a company managing medical clinic services, including business contracting, finance, staffing and ancillary support for several medical clinics in San Diego. She is responsible for the expansion and daily operation of the business functions of the medical clinics managed by HADD Group, and she has extensive knowledge and experience in healthcare business development.

Viet Tran has over 30 years of experience in engineering research, development and management. He has made numerous contributions to national network security and technology. He led the initial Naval Interoperability Profiles that set a solid foundation for future naval airborne network development. He also led a team of 50 engineers, doctorates and scientists delivering an airborne network system for the Navy’s first carrier-based unmanned aircraft. As Astiva Health’s Chief Operating and Technology Officer, member satisfaction has been his top priority. He is committed to protecting valuable data for Astiva members and providers. He constantly strives for leaner and more effective operations.

Tyler Diep is Vice President, Sales, Marketing and Provider Relations at Astiva Health. His responsibilities include handling special projects for the board of directors, as well as overseeing the sales, marketing and provider relations department. During his tenure, he tripled the membership of Astiva Health. He previously served as councilman and vice mayor of the City of Westminster, California. He immigrated to the U.S. with his parents and graduated from San Diego State with a bachelor’s degree in public administration.

Recent News

chart

SUIC Worldwide Holdings Ltd. (OTC: SUIC)

The QualityStocks Daily Newsletter would like to spotlightFathom SUIC Worldwide Holdings Ltd. (OTC: SUIC) .

SUIC Worldwide Holdings (OTC: SUIC), a provider of research and development, venture financing and investment for private and public companies, announced that it has selected IBN, a multifaceted financial news and publishing company for private and public entities, to assist with its corporate communications initiatives. Seeking to enhance and streamline existing processes and establish new and exciting business models, SUIC Worldwide Holdings targets investment in companies operating in the areas of internet of things ("IoT"), cloud computing, mobile payments, big data, blockchain, artificial intelligence and global franchising. As part of the client partner relationship, IBN will generate greater awareness for SUIC Worldwide Holdings through leveraging its investor based distribution network of 5,000+ key syndication outlets, various newsletters, social media channels, wire services via InvestorWire, blogs and other outreach tools.

In addition, SUIC, along with Boom Fintech Inc., a fully owned subsidiary of Beneway Holdings Group Ltd. USA, today announced an agreement with BD Bankers to access credit of up to $100 million in intellectual property ("IP") financing intended for the integration of advance systems and fintech patents held by Boom Fintech Inc. The move brings substantial support for the company's global partner merchants and franchisees, bolsters supply chain integration for suppliers and accelerates plans for an initial public offering of Beneway USA. "SUIC is the biggest investor, shareholder and major operating partner of Beneway USA. This is an opportunity for SUIC to optimize our overall performance as these strategic collaborations come at a crucial moment as advanced patent technology innovations have become available. We believe that this will strongly support our business partners, merchants and franchisees and drive our collective efficiency and growth in the near future," said Hank Wang, CEO of SUIC. "We are intent in achieving the highest value for our shareholders. We highly value the trust of our customers and partners in our successful expertise and integrated supply chain over the years."

To view the full press release, visit https://ibn.fm/nhr22 and https://ibn.fm/1PkFl

SUIC Worldwide Holdings Ltd. (OTC: SUIC) provides research and development, venture financing and investment for private and public companies that develop products and services in the areas of Internet of Things, cloud computing, mobile payments, Big Data, blockchain, artificial intelligence and global franchising. The company seeks to enhance and streamline existing processes and establish new and exciting business models that will create revolutionary products and services.

SUIC is the largest shareholder and major operating partner of Beneway Holdings Group. The I.Hart Group, a subsidiary of Beneway, currently operates 150 global chain and franchised locations under a variety of brands. It is working on integrating more successful chains to enter the U.S. chain and franchise market in all 50 states. It is replicating its successful multi-branding business model and teaming up with top U.S. real estate firms, shopping malls and associated groups to expand and achieve its target of 750 chain and franchise locations in the near future.

The company is headquartered in Flushing, New York, with offices in San Francisco, Taiwan and Malaysia.

Portfolio

SUIC works with Beneway in several business ventures, with focus on the following:

  • Fintech – Through Boom Fintech, the major subsidiary of Beneway USA, the company holds nine revolutionary fintech patents. Boom Fintech integrates payment systems, electronic invoice devices, mobile cash registers, POS system devices and ERP, as well Big Data + AI and other services, to ALL-IN-ONE products that provide standardized intellectual property that’s modular to all industries, from chain department stores to night market vendors. Beneway Holdings Group connects borrowers and lenders, building strategic partnerships by bridging the various stakeholders to provide a holistic financial delivery ecosystem and to integrate advanced systems and finance its global merchants and franchisees.
  • Food Industry Supply Chain Integration – SUIC and Beneway will partner with international trade financiers to support the huge demand for raw material import/export between the U.S. and Asia. SUIC and Beneway are looking to raise funds from an IPO and the capital markets to support mergers and acquisitions of U.S. mid- and upper-stream food industry suppliers.
  • Global Chain and Franchise Expansion – Through I.Hart catering group, SUIC and Beneway are working to bring reputable and distinguished overseas food product brands to the U.S. and around the world. It is working on integrating more successful chains to enter the U.S. chain and franchise market in all 50 states. It is replicating its successful multi-branding business model and teaming up with top U.S. real estate firms, shopping malls and associated groups for faster expansion.
  • Other Supply Chain Integration – Beneway has identified several additional industries for future expansion, including medical and health care, high-tech digital AI systems, environmental protection and energy-related production.

Market Opportunity

An analysis by Growth Market Reports, a full-service market research and business consulting organization, estimated that the value of the global Asian food market was $437.15 billion in 2022. The market value is projected to reach approximately $805.08 billion by 2031, expanding at a CAGR of 7.1% during the forecast period.

Asian cuisine is well known for its diversity, with a wide range of flavors, ingredients and cooking techniques influenced by various factors such as climate, geography, history and cultural practices. The report states that Asian food outlets are expanding at a tremendous rate in the U.S. and Europe due to rising consumer demand. Demand is driven by various factors, including the growing interest in global authentic flavors and the nutritional benefits that Asian food offers. Consumers have become increasingly exploratory with their food choices, according to the report.

McKinsey Consultants estimate that, by 2025, the global supply chain financial market will reach $20 trillion. At present, 60% of the global participants are small and medium-sized retail companies, representing the target customers of SUIC and its subsidiary. Recent Juniper Research shows that global digital commerce transaction value will also pass $20 trillion by 2027.

Management Team

Hank Wang is CEO of SUIC. Since 2018, he has served as CEO of the I.Hart Group. Prior to joining I.Hart, he was Secretary General of Taiwan Quantitative Hedging Development Association. He graduated from Tamkang University in Taiwan with a Bachelor of Finance degree.

Elena Lin is associate CFO of SUIC. She previously served as CEO of Monga Chicken. In 2015, she was recognized as one of Taiwan’s Top 100 Managers of the Year. She holds a master’s degree from the Kaohsiung University of Hospitality and Tourism’s Institute of Food Culture and Catering Innovation in Taiwan.

Elton Han is associate CTO of SUIC. He is also currently Director of Food and Beverage Development for the I.Hart Group. He also holds a position with the Taiwan International Young Chefs Association. He previously served as Executive Chef of Hanbilou, Huashan Guanzhi, Daye Group.

SUIC Worldwide Holdings Ltd. (OTC: SUIC), closed Tuesday's trading session at $1.8, even for the day. The average volume for the last 3 months is and the stock's 52-week low/high is $0.95/$3.00.

Recent News

Bravo Multinational Inc. (OTC: BRVO)

The QualityStocks Daily Newsletter would like to spotlightFathom Bravo Multinational Inc. (OTC: BRVO).

Bravo (OTC: BRVO), a company actively exploring opportunities in the entertainment, hospitality and technology sectors, is looking at streaming to generate long-term value for its shareholders through high-growth business ventures. "Bravo recently announced entering into a purchase agreement to acquire the assets of Streaming TVEE Inc., solidifying its entry into the video streaming industry. The company's strategic move establishes the business foundation for the previously announced flagship offering, TVee NOW(TM), which is expected to launch a Beta version during Q1 2024. The streaming service will be available for download in the Roku Channel Store, Apple Store and Google Play Store… TVee NOW intends to offer traditional broadcast television, encompassing cable and satellite networks, through a joint venture with a third party, which is set to close at a later date… The agreement also includes acquiring the over-the-top (‘OTT') streaming technology license," a recent article reads. "Fueling this transformative journey is a commitment to technical innovation, where state-of-the-art features and cutting-edge technology converge to create a seamless and immersive streaming experience," Bravo CEO Grant Cramer said. "Viewers can expect a user-friendly interface, enhanced streaming quality, and innovative features that elevate the entertainment quotient."

To view the full article, visit https://ibn.fm/LxvSs

Bravo Multinational Inc. (OTC: BRVO) actively explores opportunities in the entertainment, hospitality and technology sectors to generate long-term value for its shareholders through high-growth business ventures. Currently focused on pioneering innovative solutions in the digital content landscape, the company’s goal is to provide cutting-edge and diverse content experiences to a global audience.

In February 2024, Bravo finalized a deal to acquire Streaming TVEE Inc.’s assets, marking a pivotal step in establishing its flagship offering, aptly named TVee NOW™. The acquired assets provide the company with the technology and foundation to soon offer streaming services including Video-On-Demand (VOD) and linear TV, often referred to as traditional broadcast TV, which encompasses cable and satellite networks, through a joint venture with Pythia Experiences.

TVee NOW™ plans to offer a wide range of on-demand content, including movies, series, concerts and original programming, at minimal or no cost to viewers. The service, set for beta launch in Q1 2024, will be accessible across various devices, with dedicated apps available on platforms such as Roku, Apple and Google Play stores, reinforcing Bravo’s commitment to innovation and audience accessibility.

The company is based in Virginia Beach, Virginia, with a second office soon opening in Las Vegas, Nevada.

Products

TVee NOW’s streaming service will offer a portion of its content for free, catering to the growing demographic of cord-cutters and aligning with the dynamic landscape of advertising-based video on demand (AVOD) streaming. Bravo’s Over-The-Top (OTT) streaming platform is specifically crafted to deliver content directly to viewers via the internet, accessible through a browser or freely downloadable apps on smartphones, tablets and smart TVs.

Bravo’s planned strategic approach for content is to first integrate partnered Free Ad-Supported TV (FAST) channels, programmatic advertising and a tiered revenue sharing model. Additionally, the company plans to complete the deal with Pythia Experiences, enabling a hybrid model comprised of AVOD, utilizing programmatic advertising through ad servers, and Subscription-based Video-on-Demand (SVOD), which the company plans to offer at competitive rates compared to other services. With this model completed, Bravo can bridge the gap until the company can ultimately create its own original content.

Through the asset purchase agreement with Streaming TVEE, Inc., the company obtained exclusive rights, image and likeness, label waivers and exploitation rights for streaming of 117 high-definition music and comedy performances, each offering a director’s cut and multiple camera perspectives. Some of the music artists include Snoop Dogg, H.E.R., Kings of Leon, Alicia Keys and Bone Thugs-N-Harmony, along with comedic performances from Bill Burr, Jim Gaffigan, Kristen Schaal, Rob Delaney and others. This original footage will allow Bravo to recreate shows in diverse formats, which can showcase these concert films in a compelling full-feature format.

Market Opportunity

A report from Fortune Business Insights, a global market research and reporting firm, estimated the global video streaming market at $455.45 billion in 2022. It is projected to grow from $554.33 billion in 2023 to $1.9 trillion by 2030, achieving a CAGR of 19.3% during the forecast period.

Growth drivers, according to the report, include a rising number of users of Video-on-Demand services (YouTube, for example) worldwide and the growing adoption of OTT content providers (like Netflix and Hulu, among many others) by consumers, as well as consumers’ willingness to spend more for streaming video content.

Management Team

Grant Cramer is CEO and Director of Bravo. He has more than 30 years of experience as an actor, writer, director, producer and production executive. As founder and president of Landafar Entertainment and Global Pictures Media, he has overseen development and production of 14 feature films. He executive produced Lone Survivor, November Man and Arctic Dogs. He produced And So It Goes, directed by Rob Reiner and starring Michael Douglas and Diane Keaton. His short film Say Goodnight, Michael won several awards, including the Grand Jury Award at the New York International Independent Film Festival.

Frank Hagan is Bravo’s President and Director. He is an Emmy-nominated producer with over 30 years of experience in the entertainment industry. He is the former Programming Director and GM of QTN. He has produced shows for major networks and companies, including Discovery Channel, History Channel and Relativity Media. Most recently, he served as a consulting producer for Electric Entertainment’s ElectricNOW! and the Saturn Awards and worked as a regular weekly panelist for Outlaw Internet Radio.

Richard Kaiser is CFO and Director of Bravo. He is also CFO at BioForce Nanosciences Holdings Inc. and Gold Rock Holdings Inc. He serves on the board of Element Global Inc., a wholly owned subsidiary of BioForce Nanosciences Holdings Inc. He previously directed investor relations for Royal Standard Minerals Inc. and Scorpio Mining Inc. He was also Head of Corporate Communication and Investor Relations at Air Packaging Technologies Inc. and Puff Pack Industries Inc.

Kayla Slick is COO and Director at Bravo. She has more than 15 years of experience in various industries, including finance, healthcare, technology, retail, hospitality and entertainment. She co-founded The PRIME Symposium and significantly increased revenues for INSIDE Public Accounting. She held positions at Interactive Digital Solutions, where she founded the Sales Development Program and was later promoted to Marketing Communications Director for IDS’ flagship virtual patient observation product.

Bravo Multinational Inc. (OTC: BRVO), closed Tuesday's trading session at $0.24, even for the day. The average volume for the last 3 months is and the stock's 52-week low/high is $0.05/$0.95.

Recent News

Genprex Inc. (NASDAQ: GNPX)

The QualityStocks Daily Newsletter would like to spotlight Genprex Inc. (NASDAQ: GNPX).

Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes. The company today announced that its research collaborators have published positive preclinical data for the NPRL2 tumor suppressor gene, utilizing Genprex's non-viral Oncoprex(R) Delivery System, in KRAS/STK11 mutant anti-PD1 resistant non-small cell lung cancer ("NSCLC") in a humanized mouse model. "These positive preclinical data are very encouraging and support NPRL2 gene therapy as a potential treatment for a sub-group of NSCLC in which patients traditionally are resistant to existing therapies," said Rodney Varner, president, chairman and CEO at Genprex. "We believe this data could support the potential for a new drug candidate in our pipeline, and it also provides further evidence that the Oncoprex(R) Delivery System has the ability to be successful using genes other than the TUSC2 gene we are already using in clinical trials with Reqorsa(R)."

To view the full press release, visit https://ibn.fm/ZnwKH

Genprex Inc. (GNPX) is a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.

Research and Development

Genprex holds a portfolio of 30 issued and two pending patents covering its technologies and targeted molecular therapies. The company’s research and development program is focused on identifying and developing leading-edge gene therapies that can be used alone or in combination with other therapies for treatment of cancer.

Genprex’s initial product candidate is Oncoprex™, an immunogene therapy for the treatment of non-small cell lung cancer (NSCLC). Oncoprex works by interrupting cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis (or programmed cell death) in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.

Preclinical research is being conducted with the goal of developing Oncoprex to be administered with targeted therapies in other solid tumors, and with immunotherapies in NSCLC and other solid tumors. In addition, Genprex has conducted and plans to continue research into other tumor suppressor genes associated with chromosome 3p21.3, as well as other potential applications of the company’s immunogene therapy platform.

Clinical Trials

Genprex is currently conducting the second phase of a phase I/II clinical trial at the University of Texas MD Anderson Cancer Center in Houston. The company plans to expand its clinical program by adding a new clinical study evaluating Oncoprex™ in combination with a checkpoint inhibitor for treatment of Stage IV or recurrent NSCLC. In research presented at the 2017 Annual Meeting of the American Association of Cancer Research in Washington, D.C., Genprex’s collaborators showed that TUSC2 in combination with PD-1 checkpoint inhibition has a significantly greater anti-tumor effect in lung cancer than either agent alone. The research also shows that TUSC2 in combination with PD-1 blockade has synergistic activity in upregulating natural killer (NK) cells, correlating with prolonged survival in mice.

TUSC2 (Tumor Suppressor Candidate 2) is a tumor suppressor gene that is absent or deficient in cancer cells of many different cancer types.

The Market

Genprex technologies seek to bridge a critical gap by combining with targeted therapies and immunotherapies to provide treatments to large patient populations who would otherwise not be candidates for those therapies or who have become resistant to them. Genprex technologies are being developed to overcome genomic limitations which are inherent in targeted therapies and immunotherapies in order to provide new treatment solutions to large cancer populations, such as those with lung cancer.

Each year, more people die of lung cancer than of colon, breast and prostate cancers combined. NSCLC is the most common type of lung cancer, accounting for about 85 percent of all lung cancers, according to the American Cancer Society (“ACS”). Despite radical advances in drug development and novel therapeutic standards, survival for late stage lung cancer has not improved significantly in the past 25 years.

Senior Management

Chairman and Chief Executive Officer J. Rodney Varner, JD, is a co-founder of Genprex and has served in these roles since August 2012. He has more than 35 years of legal experience with large and small law firms and as outside general counsel of a Nasdaq-listed company. Varner has served as counsel in company formation, mergers and acquisitions, capital raising, other business transactions, protection of trade secrets and other intellectual property, real estate, and business litigation. He is a member of the State Bar of Texas and has been admitted to practice before the U.S. Court of Appeals for the Fifth Court and the U.S. Tax Court.

Julien L. Pham, M.D., MPH, is president and chief operating officer of Genprex. In March 2013, Dr. Pham co-founded RubiconMD, a healthcare IT company that connects primary care providers to specialists for additional guidance and opinions on medical cases and served as its chief medical officer. He has served on the faculty at Harvard Medical School’s Brigham and Women’s Hospital and is a board-certified internal medicine doctor and nephrologist.

Ryan M. Confer, MS, has served as Genprex chief financial officer since September 2016. Confer has more than 10 years of executive experience in planning, launching, developing, and growing emerging technology companies and has served in the chief operating and chief financial roles for non-profit and for-profit entities since 2008. Confer has also served as an international business development consultant for the University of Texas at Austin’s IC2 Institute, where he focused on evaluating the commercialization potential of nascent technologies in domestic and international markets applicable to technology incubator programs associated with the University. Confer holds a BS in finance and legal studies from Bloomsburg University of Pennsylvania and an MS in technology commercialization from the McCombs School of Business at the University of Texas at Austin.

Jan Stevens, RN, is vice president of Clinical Operations. Stevens has nearly 20 years of comprehensive clinical operations experience in the biopharma industry and a specialization in early-to-late stage oncology companies. Stevens joined the company to help support the various clinical development programs for Oncoprex™.

Genprex Inc. (NASDAQ: GNPX), closed Tuesday's trading session at $2.84, off by 4.3771%, on 56,497 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $2.50/$46.00.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be featured in two April investor conferences, including the MedInvest Biotech & Pharma Investor Conference and the 14th annual LD Micro Invitational. CNS Pharmaceuticals CEO John Climaco will present at the one-day MedInvest Biotech & Pharma Investor event, which is scheduled for April 4, 2024; Climaco's presentation will begin at 4:25 p.m. ET. The presentation can be watched live on the company's website. Climaco will also present at the LD Micro Invitational, which will be held April 9, 2024; his presentation will begin at 1 p.m. ET.

To view the Micro Invitational presentation, visit https://ibn.fm/QytSa

To view the full press release, visit https://ibn.fm/Ty4L5

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Tuesday's trading session at $0.3075, off by 14.5359%, on 291,397 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.229/$4.40.

Recent News

FingerMotion Inc. (NASDAQ: FNGR)

The QualityStocks Daily Newsletter would like to spotlight FingerMotion Inc. (NASDAQ: FNGR) .

The rapid proliferation of optimized mobile payments in China is making the country an increasingly convenient travel location for foreigners. China's mobile payment segment has developed extremely rapidly over the past several years, and the East Asian nation is now a global leader in the relatively young space. Mobile payment systems are services that allow customers to pay for goods and services through portable electronic devices, including mobile cell phones or tablets, allowing them to make payments or send money to loved ones quickly and conveniently. While these systems have existed for more than a decade, their popularity surged during the coronavirus pandemic because they allowed for contactless transactions between businesses and consumers. The emergence of various mobile payment solutions providers such as FingerMotion Inc. (NASDAQ: FNGR) is undoubtedly helping to drive innovation within the space, and consumers are reaping the benefits of those innovations.

FingerMotion Inc. (NASDAQ: FNGR) is an evolving technological company with core competencies in mobile payment and recharge platform solutions in China. FingerMotion is in the process of developing additional value-added technologies to market to users.

Founded in 2016, FingerMotion’s goal is to serve over a billion users in the Chinese market and expand its model to other regional markets. The company has offices in Hong Kong, Shanghai and New York City.

Current Offerings

FingerMotion is analyzing and transforming mobile data to improve the lifestyle of the public through technology and innovation. The company’s current offerings include:

  • Telecommunications Products and Services – FingerMotion’s proprietary universal exchange platform, ‘PigeonHole Integration System (PIS)’, offers seamless integration between telecom operators and online stores. The service platform’s offerings include top up and recharge, data plan, mobile phone, loyalty points redemption and subscription plans. The platform offers reliable and secure transactions, real-time reconciliation, simple integration for partners and efficient settlements.
  • SMS and MMS Services – The integrated platform is registered as FingerMotion’s IP in China and provides a robust back-end control panel for corporate partners to manage their own messaging settings. FingerMotion’s clients range from insurance to financial industries, ecommerce firms, airlines and more. The platform offers competitive pricing for partners and provides quick and efficient review to meet timely marketing initiatives.
  • Big Data Insights – FingerMotion brings Big Data-enabled insurance solutions through its Big Data Insights arm, Sapientus. The company’s strategic partnerships with the largest Chinese telecommunications giants allow access to uncover behavior insights through geolocation and mobile data usage. Its Big Data offerings include risk scoring, precise marketing, simplified underwriting and customized products.
  • Rich Communication Services (RCS) – FingerMotion’s RCS platform will be a proprietary business messaging solution that enables businesses and brands to communicate their services to customers via 5G infrastructure. The company expects its RCS platform to offer a better user experience, more efficiency and cost-effectiveness when compared to other solutions.

Telecommunications and Insurtech Markets

The global telecommunications market was valued at $1.74 trillion in 2019 and is expected to grow at a CAGR of 5% from 2020 to 2027. The steady increase is expected to be driven by the adoption of 5G and the increased popularity of Internet of Things (IoT) applications.

The Chinese telecom market was valued at $254.1 billion in 2017 and is also constantly expanding. The current Chinese telecom market is dominated by three mobile operators – China Mobile, China Unicom and China Telecom, which together are responsible for around 1.6 billion active subscribers (https://ibn.fm/zfwy9).

In addition, the insurtech (insurance technology) market was valued at $2.72 billion globally in 2020 and is expected to grow at a CAGR of 48.8% from 2021 to 2028. The large increase is attributed to the rising use of technology solutions for everyday activities like acquiring insurance coverage (https://ibn.fm/TGo7D).

Through its proprietary platforms and technologies, FingerMotion is uniquely positioned to capitalize on the telecom and insurtech markets’ growth and opportunities.

Management Team

Martin J. Shen is the Chief Executive Officer of FingerMotion Inc. He has over 15 years of experience in senior management roles within entrepreneurial startups and large multinational corporations. He has acquired a wide range of corporate management, financial oversight and operation administration expertise through these roles. In his most recent role, he founded Imperial Distributors (formerly known as AP Martin Pharmaceutical Supplies Ltd.), establishing the company as the preferred choice for distributional support to regional pharmacies throughout Western Canada. Before founding Imperial, Mr. Shen served as the Chief Operating Officer and Chief Financial Officer at Wales and Son Industrial (formerly Weir Minerals), a firm specializing in global delivery and support for mining slurry equipment. He began his career at PricewaterhouseCoopers in Vancouver, with work tours in the tax department in Singapore and the tax audit and advisory group in Hong Kong. Mr. Shen is a U.S. Certified Public Accountant and holds a Bachelor of Science from the University of British Columbia.

Lee Yew Hon is the company’s Chief Financial Officer. From 2006 until November 2020, he was the Chief Financial Officer of Cubinet Interactive Group of Companies, and he also took on the Chief Operating Officer role in 2011. During his tenure, he was instrumental in leading Cubinet and building teams across the Southeast Asia region, setting up financial processes within a short time. Mr. Lee spearheaded the growth of Cubinet to other regions, including Europe, the Middle East and Russia. He received his diploma from Tunku Abdul Rahman College in 1996. He is a Chartered Accountant, a member of the Malaysia Institute of Accountants (MIA) and an Associate Member of the Chartered Institute of Management Accountants, UK (ACMA).

Li Li is the Senior Vice President of FingerMotion. She recently served as Advisor to Shenzhen WuYiKa Technology Co. Ltd., a comprehensive service platform dedicated to online service distribution and payment. The company has become a fast and efficient provider of new media marketing solutions for the mobile internet. She has held high-level management positions with multiple industry names, including Hangzhou JiuYue Information Technology Co. Ltd. and Hangzhou LingXuan Information Technology. Ms. Li started her career in 2004, founding Shanghai ChuangYeZZ Network Technology Co. Ltd. and serving as its Vice President. With the close cooperation of local operators, the company launched SMS, MMS, WAP, mobile JAVA games, Hunan Satellite TV e-magazine and other wireless internet services to meet the rapid development of wireless internet and application requirements. She received her degree from Nanjing Academy of Engineering.

FingerMotion Inc. (FNGR), closed Tuesday's trading session at $2.21, off by 8.6777%, on 158,746 volume. The average volume for the last 3 months is 286,722 and the stock's 52-week low/high is $1.28/$7.97.

Recent News

NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW)

The QualityStocks Daily Newsletter would like to spotlight NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW).

The nascent Web3 game development segment is poised to benefit from the incorporation of decentralized physical infrastructure networks (DePINs). These networks would act as the underlying framework for decentralized applications (DApps), such as Web3 games, and allow both developers and end users to enjoy a smoother end experience. Building Web3 games on DePINs could allow for the creation of a new layer-2 blockchain that combines video rendering with artificial intelligence (AI) data processing to ease developers into Web3 gaming. Decentralized physical infrastructure network provider (DePINs) and decentralized processing network GAIMIN recently partnered with Movement Labs and BNB Chain to launch an L2 blockchain that will incorporate Web3 technology into gaming. Web3 isn't only finding use cases in gaming. E-commerce businesses such as NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW) are leveraging this technology to help clients reach a bigger target consumer base while enhancing data security, personalization and enabling data-driven decision making.

NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW), a next generation e-commerce platform, was created with vision and purpose to capitalize on high growth sectors and global markets. The company collaborates with businesses – large and small – to simplify and accelerate online commerce and uniquely enables customers and partners to optimize their e-commerce reach, presence and revenue. NextPlat recently launched a new e-commerce development program to provide American businesses with easy access to the massive Chinese consumer market.

Current Initiatives

NextPlat provides cutting edge technology in an advanced e-commerce ecosystem. The company is actively expanding its global network of online storefronts serving thousands of consumers, enterprises and governments. The company also has developed a next generation platform built for Web3 that enables the creation and sale of digital assets, as well as optimizing e-commerce transactions and business building activities. The company’s current initiatives include:

  • E-Commerce Development Program – In April 2023, NextPlat announced it had entered into a merchant sourcing agreement with Alibaba.com Singapore E-Commerce Private Limited (“Alibaba”) and its Tmall Global e-commerce platform whereby the two companies will collaborate to increase the sale of products produced and sold by American companies to the multi-trillion-dollar Chinese consumer market. Alibaba’s Tmall Global e-commerce platform will provide NextPlat customers a turn-key solution through which products can be sold to the Chinese consumer market. The launch of the Florida E-Commerce Development Program is the first in a series of new NextPlat programs designed to assist U.S. businesses in expanding their online sales capabilities to reach new international customers in the Chinese market. NextPlat intends to rapidly expand this unique e-commerce development opportunity to businesses throughout the United States and all of North America, as well as Central and South America. The new development program features NextPlat’s turnkey global e-commerce solution for customers and leverages NextPlat’s relationships with key partners, including Tmall Global, China’s largest cross-border B2C online marketplace.
  • Progressive Care Inc. – In August 2022, NextPlat completed a strategic $7 million investment in Progressive Care Inc. (OTCQB: RXMD), a personalized health care services and technology company. In a news release announcing the investment, NextPlat CEO Charles M. Fernandez noted that the company is “committed to harnessing the power of digital technologies to capitalize on the ongoing digital transformation of Progressive Care and the entire health care industry.” NextPlat intends to accelerate Progressive Care’s digital health care transformation with the launch of a new e-commerce platform for health care products later this year.
  • NextPlat NFT Platform – Building on its existing e-commerce initiatives, NextPlat is working to bridge the gap between tangible and digital e-commerce marketplaces by incorporating burgeoning Web3 technologies. The company intends to launch a fully integrated NFT platform in the coming months that will enable brands to create, manage and authenticate digital assets while serving as a new source of revenue for NextPlat. Through this model, the company will receive a portion of the revenue generated from branded NFT drops, as well as subsequent secondary market transactions.
  • Global Telesat Communications and Orbital SatCom Corp. – Targeting both domestic and international markets, NextPlat’s subsidiaries leverage partnerships with major e-commerce platforms such as Amazon, Alibaba, eBay and Walmart to serve a growing base that includes more than 50,000 corporate, governmental and individual customers. In total, the brands market more than 10,000 individual products, with a focus on satellite-based connectivity solutions. In addition to exploring accretive M&A opportunities, NextPlat aims to diversify its range of products and broaden its geographic footprint moving forward in an effort to better capitalize on the tremendous growth potential in the United States, Europe and Asia.

“Our goal for 2023 and beyond is to leverage our improved operational capabilities and enhanced leadership team as we expand our offerings in communications and connectivity into the high-growth health care market where we intend to launch an array of innovative new offerings,” Fernandez said in a March 2023 news release detailing the company’s record top-line performance. “Although there remain supply chain headwinds and the challenge of global inflation, we are confident that we have the right combination of market-tested expertise, technology and partnerships that will enable us to bring the power of e-commerce to more customers, brands and industries in the United States and abroad.”

Market Opportunity

The rapid growth of e-commerce over the last decade is expected to continue for the foreseeable future. According to data published by Forbes, roughly 20.8% of all retail purchases are expected to take place online in 2023, accounting for total sales of $6.31 trillion worldwide. It total, e-commerce sales are expected to grow by 10.4% YoY in 2023, accounting for a whopping 24% of all retail purchases by 2026.

For NextPlat, existing partnerships in the industry could be key to capitalizing on this growth. The Forbes report indicates that Amazon accounts for roughly 38.7% of e-commerce sales, while sites like Walmart, eBay and Alibaba round out the list of most visited e-commerce websites. Alibaba is especially interesting due to NextPlat’s recent strategic merchant sourcing agreement with Tmall Global. The Chinese market is “mammoth,” as a recent Alizila report noted. The country’s annual online retail sales of physical goods have nearly doubled in the last five years, reaching approximately 13.8 trillion yuan in 2022, which is nearly $2 trillion USD.

The health care portion of the e-commerce market is generating particularly bullish forecasts, bolstered by the continued adoption of the 340B Drug Pricing Program in the U.S., which requires most drug manufacturers to provide outpatient drugs to covered entities at significantly reduced prices. Industry reports suggest that the global health care e-commerce market will expand at a compound annual growth rate of 16.8% from 2022 to 2030, climbing to a value of more than $1.37 trillion by the end of the forecast period.

Management Team

Charles M. Fernandez, CEO, Executive Chairman and Director of NextPlat, has over three decades of experience in identifying profitable start-up and dislocation opportunities, building significant value and executing exit strategies as an entrepreneur and global investor. Successful across multiple sectors, Fortune Magazine actually labeled Fernandez ‘a restructuring whiz’. As President of Fairholme Capital Management, which he joined in 2008, Mr. Fernandez co-managed all three Fairholme funds and brought in a $2 billion gain for shareholders. Throughout his impressive career, he has participated in more than 100 significant mergers, acquisitions and product development projects across multiple industries. Mr. Fernandez was the founder, Chairman and CEO of eApeiron Solutions LLC, a brand protection and e-commerce company in partnership with Alibaba (NYSE: BABA) and Eastman Kodak (NYSE: KODK), which was successfully sold to Smartrac, a unit of Avery Dennison Corp. (NYSE: AVY).

Rodney Barreto is Chairman and CEO of the Barreto Group and Director of Nextplat. Mr. Barreto’s business career spans over 35 years, including his role at the Barreto Group and, earlier, as the founding partner of Floridian Partners LLC, a corporate and public affairs consulting firm recognized by policy makers as one of the top in its industry in Florida. He chaired the Super Bowl Host Committee in 2007, 2010 and 2020, helping to raise more than $100 million for the success of Miami Super Bowls. As a philanthropist and conservationist, Mr. Barreto is also a three-time appointee to the Florida Fish and Wildlife Conservation Commission, where he has served for over 10 years including holding the title of Chairman eight times. He has twice chaired the Annual U.S. Conference of Mayors, was Chairman of the 1999 Breeder’s Cup Championship held in South Florida and was the Chairman of the 1999 Sister Cities International Convention in Miami. Currently, Mr. Barreto is the Membership Chairman of the Florida Council of 100, and a member of the Boards of Fairchild Tropical Botanic Garden, the Baptist Health South Florida Giving Society, the Bonefish and Tarpon Trust, the Guy Harvey Ocean Foundation, and a member of Miami Dade County Schools Superintendent Carvalho’s Business Advisory Council. Prior to his career in public affairs and real estate, Mr. Barreto was a City of Miami police officer and is a member of the Florida Highway Patrol Advisory Council.

NextPlat Corp. (NXPL), closed Tuesday's trading session at $1.51, off by 3.5267%, on 19,415 volume. The average volume for the last 3 months is 12,788 and the stock's 52-week low/high is $1.2101/$4.26.

Recent News

Correlate Energy Corp. (OTCQB: CIPI)

The QualityStocks Daily Newsletter would like to spotlight Correlate Energy Corp. (OTCQB: CIPI).

Distributed energy solutions company Correlate Energy Corp. is focused on boosting businesses with a clean green focus, helping them to better plan, fund, and manage their building energy profiles

Green economic factors are becoming increasingly important to businesses and governments, as evidenced by pollution-reducing measures taken by the federal and state governments, and at the local level as with New York City

The most recent measure of that commitment is the March 20 announcement by the EPA to roll out finalized national pollution standards for cars, pickups, and other vehicles

Correlate's strategy includes the development and sale of localized clean energy solutions and microgrids for companies, while retaining possession of some energy systems, which helps affordability for the client while supporting Correlate's dependable revenue stream

In tandem with efforts by different levels of government to continue building a "green economy" through reduction of carbon pollution and the promotion of associated technologies, local governments and many businesses are looking for affordable ways to adopt cleaner environmental standards for their operations and buildings. Distributed energy solutions company Correlate Energy (OTCQB: CIPI) is working with U.S. businesses and government programs to make solar power and other green energy solutions accessible to mid-tier companies that are often overlooked by large energy companies and consulting firms (https://ibn.fm/DMDcd). Correlate is tapping into an economic trend spurred in part by an international pact to cut pollution nation-by-nation around the world, known as the Paris Agreement.

Correlate Energy Corp. (OTCQB: CIPI) is a publicly-traded company strategically positioned to capitalize on America’s unstoppable trend toward decentralized energy generation.

The energy grid in the U.S. is insufficient for the booming clean energy trend, and current infrastructure is limiting green energy distribution. Constructing the needed infrastructure to address this demand imbalance will cost billions and be far too slow, positioning decentralized systems, like those on offer from Correlate, in a key position for heightened demand.

Correlate has identified several key economic drivers powering the decentralized energy trend, including:

  1. Real Cost Savings – Customer pays zero money down and gets an instant electrical price discount to current rates.
  2. Massive Project Investment Funding – The International Energy Agency estimates that over one billion dollars per day will be invested in solar energy in 2023.
  3. Consistent Long-Term Incentives – The Inflation Reduction Act is a game-changer, supercharging renewables with $1.2 trillion in tax credits for 10 years of market support.
  4. Robust Customer Demand – Wood Mackenzie expects the U.S. solar industry to nearly triple in size over the next five years.

Correlate’s team of multi-decade experts who have worked with renowned global brands are positioning the company to make the most of this opportunity while consolidating a fragmented industry. Collectively, the team has developed, financed and deployed over $2 billion in clean energy projects to date.

Three-Pronged Strategy

Correlate is leveraging a three-pronged strategy aimed at driving shareholder value:

  1. Sell – Correlate seeks to finance, develop and profitably sell localized clean energy solutions and microgrids to industrial, commercial and residential customers.
  2. Retain – Correlate plans to retain ownership of some of these energy systems and thereby realize ongoing, reliable cash flow.
  3. Acquire – Correlate seeks to acquire proven renewable energy companies in order to exponentially grow earnings per share for investors.

This strategy is enhanced by current investment trends. Clean energy earnings are being sought after by investors. In Q4 2022, the median EBITDA multiple for green energy companies was 12.3x, according to Finerva.

Market Outlook

Over the next decade and beyond, renewable energy growth is expected to come primarily via decentralized systems like those offered by Correlate.
The Inflation Reduction Act enacted in late August 2022 is likewise expected to drive growth for the company by providing new tax incentives that reduce costs for clients and/or elevate returns to investors.

Commercial buildings consume more than 35% of the generated electricity in the U.S. and are underperforming in energy efficiency at every level. These buildings waste energy, emit too much carbon and are too costly for owners and occupants, but retrofits are not happening at the rate or scale needed.

In today’s real estate market, portfolio property owners own most commercial buildings, yet most building efficiency work is focused on single buildings, thereby missing the distinct needs of this owner class which are very different from traditional owner-occupiers. The diverse nature of commercial buildings, combined with technology and performance uncertainty, make simple energy optimization initiatives – which could greatly reduce energy use and improve building value – financially unattractive, resulting in slow adoption rates. CIPI’s financial instruments and software breakdown this issue, known as the ‘split incentive’, unlocking the majority of the addressable market.

A key portion of Correlate’s strategy relates to consolidation of what has been a fragmented industry. By uncovering opportunities to improve efficiencies through strategic M&A activities, the company intends to enhance profitability throughout its operations.

Management Team

Todd Michaels is President and CEO of CIPI and founder of Correlate. He formerly served as Vice President for Innovation at SunEdison and Senior Director Distributed Solar at NRG Energy. He founded Correlate in 2015 and has 16 years of experience in the energy industry. He graduated from Indiana University with a B.S. in Computer Information Systems.

Channing Chen is CFO at CIPI and Correlate Inc. and brings over 16 years of experience in the solar industry as a developer, financier, and business unit leader. He has held executive management roles at Solar Power Partners (acquired by NRG Energy), where he was a founding employee, SunEdison, and NRG Energy (NYSE: NRG). Most recently, Mr. Chen was founder and Managing Partner at Breakaway Energy Partners LLC – a distributed energy financing and market-making platform. To date, Mr. Chen and his teams have raised over $1.5 billion in financing across residential, commercial, and utility scale solar and energy storage projects representing over 400 MWs. He holds a B.A. in Environmental Chemistry from the University of California at San Diego and an MBA from the University of Southern California. He is also an advisor and early-stage investor to several startup companies in the renewable energy space.

Dave Bailey is Chief Revenue Officer of Correlate Inc. With over 15 years of executive sales, supply chain management, and energy efficiency experience, he is responsible for ensuring the success of the National Commercial Sales Unit across multiple regional project teams. Mr. Bailey created and launched the Transformation Services team while at Wesco for its multibillion-dollar Distributed Energy Resource division, formerly Westinghouse. His focus was on IoT-enabled efficiency and plant floor automation-based services. Before that, he spent several years in Global Account Sales Management, with GE Supply as a Program Manager, and is a Commercial Leadership Program graduate. Mr. Bailey received his B.S. in Mechanical Engineering from the University of Kentucky.

Jed Freedlander is the company’s Chief Development Officer. He has a background in infrastructure development and investment and a strong legal, commercial and finance acumen. Mr. Freedlander has a proven track record in leading complex public-private partnership (P3) and energy transactions and is instrumental in driving Correlate’s strategic development initiatives.

Roger Baum is Executive VP Operations at Correlate. With over 20 years of experience at Core Construction, he brings to the company a wealth of knowledge and a strong track record in delivering successful commercial construction projects.

Jason Loyet is Director of Solar Energy for Correlate Inc. He is a cleantech executive with over 20 years of experience leading high growth solar energy and software start-ups. Mr. Loyet is a U.S. Department of Energy SunShot Catalyst award winner for his work building the Solar Site Design technology platform. Before joining the solar energy industry in 2005, he founded and sold two software companies in the streaming media (GlobalStreams) and newspaper publishing (MyCapture) industries. Mr. Loyet currently serves as a Member of the Board of Directors for the Tennessee Solar Energy Industry Association (TenneSEIA).

Correlate Energy Corp. (OTCQB: CIPI), closed Tuesday's trading session at $1.35, off by 7.5342%, on 600 volume. The average volume for the last 3 months is 3,116 and the stock's 52-week low/high is $0.3501/$2.35.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower
ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower
ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower
ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

370 N. Hayden Rd.
Suite 123-591
Scottsdale, AZ 85251
480-374-1336

Please read Disclaimers for FULL Compensation Disclosures and other disclaimers.

Copyright © .